Do analysts recommend ASLN or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Galmed Pharmaceuticals N/A -73.68% -60.88%

Do analysts recommend ASLN or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 896.40%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate ASLN or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or INM more profitable?

InMed Pharmaceuticals' return on equity of -156.08% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% InMed Pharmaceuticals N/A -156.08% -123.90%

Do analysts rate PCSA or ASLN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PCSA or ASLN more profitable?

Heatwurx's return on equity of -394.25% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Is LIAN or ASLN more profitable?

LianBio's return on equity of -33.17% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

ASLAN Pharmaceuticals (ASLN) Competitors

$0.60 0.00 (0.00%)

As of 10/2/2026

Compare

ASLN vs. GLMD, SXTP, INM, PCSA, and LIAN

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? ASLAN Pharmaceuticals's main competitors and comparable companies include Galmed Pharmaceuticals (GLMD), 60 Degrees Pharmaceuticals (SXTP), InMed Pharmaceuticals (INM), Heatwurx (PCSA), and LianBio (LIAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ASLAN Pharmaceuticals compare to Galmed Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Galmed Pharmaceuticals	Positive

Galmed Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -73.68% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Galmed Pharmaceuticals beats ASLAN Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
60 Degrees Pharmaceuticals	Neutral

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
60 Degrees Pharmaceuticals	$1.41M	3.47	-$7.36M	-$4.82	N/A

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 896.40%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

60 Degrees Pharmaceuticals beats ASLAN Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

InMed Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A

In the previous week, InMed Pharmaceuticals had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for InMed Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.32 beat ASLAN Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
InMed Pharmaceuticals	Positive

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InMed Pharmaceuticals' return on equity of -156.08% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Summary

InMed Pharmaceuticals beats ASLAN Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Heatwurx's return on equity of -394.25% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Heatwurx has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Heatwurx is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Heatwurx's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Heatwurx	Neutral
ASLAN Pharmaceuticals	Neutral

Heatwurx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Heatwurx and ASLAN Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to LianBio?

LianBio (NASDAQ:LIAN) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

LianBio's return on equity of -33.17% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

74.8% of LianBio shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LianBio has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, LianBio's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
ASLAN Pharmaceuticals	Neutral

ASLAN Pharmaceuticals has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Summary

LianBio beats ASLAN Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASLN vs. The Competition

Export

Metric	ASLAN Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.23M	$12.28B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-0.03	802.26	274.71	26.04
Price / Sales	0.10	940.01	656.46	105.13
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	-0.09	10.52	10.93	6.31
Net Income	-$44.22M	$2.86B	$3.51B	$362.16M
7 Day Performance	N/A	-1.58%	-2.00%	-1.66%
1 Month Performance	N/A	-5.55%	-6.19%	-4.68%
1 Year Performance	N/A	-2.19%	8.03%	1.57%

ASLAN Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
GLMD Galmed Pharmaceuticals	0.9453 of 5 stars	$4.59 -0.9%	N/A	-63.5%	$4.78M	N/A	N/A	20	News Coverage Gap Down High Trading Volume
SXTP 60 Degrees Pharmaceuticals	1.7525 of 5 stars	$1.29 -2.9%	$13.85 +972.8%	-75.5%	$4.54M	$1.41M	N/A	3	News Coverage Gap Up
INM InMed Pharmaceuticals	1.4595 of 5 stars	$1.35 -1.1%	N/A	-41.9%	$4.45M	$4.94M	N/A	6	Positive News Short Interest Decrease
PCSA Heatwurx	0.8252 of 5 stars	$1.60 -2.4%	N/A	-69.8%	$4.43M	N/A	N/A	12	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. GLMD, SXTP, INM, PCSA, and LIAN

How does ASLAN Pharmaceuticals compare to Galmed Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to Heatwurx?

Summary

How does ASLAN Pharmaceuticals compare to LianBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. GLMD, SXTP, INM, PCSA, and LIAN

How does ASLAN Pharmaceuticals compare to Galmed Pharmaceuticals?

Does the media refer more to ASLN or GLMD?

Which has stronger earnings and valuation, ASLN or GLMD?

Which has more risk & volatility, ASLN or GLMD?

Do institutionals & insiders have more ownership in ASLN or GLMD?

Is ASLN or GLMD more profitable?

Do analysts recommend ASLN or GLMD?

Summary

How does ASLAN Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Do institutionals and insiders have more ownership in ASLN or SXTP?

Is ASLN or SXTP more profitable?

Which has more risk and volatility, ASLN or SXTP?

Does the media prefer ASLN or SXTP?

Which has better valuation and earnings, ASLN or SXTP?

Do analysts recommend ASLN or SXTP?

Summary

How does ASLAN Pharmaceuticals compare to InMed Pharmaceuticals?

Which has preferable valuation and earnings, ASLN or INM?

Does the media favor ASLN or INM?

Do insiders and institutionals hold more shares of ASLN or INM?

Which has more volatility & risk, ASLN or INM?

Do analysts rate ASLN or INM?

Is ASLN or INM more profitable?

Summary

How does ASLAN Pharmaceuticals compare to Heatwurx?

Is PCSA or ASLN more profitable?

Which has better earnings and valuation, PCSA or ASLN?

Do analysts rate PCSA or ASLN?

Does the media favor PCSA or ASLN?

Which has more volatility and risk, PCSA or ASLN?

Do institutionals and insiders believe in PCSA or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to LianBio?

Is LIAN or ASLN more profitable?

Do institutionals and insiders hold more shares of LIAN or ASLN?

Which has more risk and volatility, LIAN or ASLN?

Does the media prefer LIAN or ASLN?

Which has stronger earnings & valuation, LIAN or ASLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools